Why the study?
Do non-losartan ARBs improve survival compared to losartan in elderly patients with heart failure?
Do non-losartan ARBs improve survival compared to losartan in elderly patients with heart failure?
Answers are grounded in this paper and cite their sources.
In elderly patients with heart failure, treatment with irbesartan, valsartan, or candesartan is associated with better survival compared to losartan, suggesting the absence of a class effect among ARBs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hudson et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: